Gatipotuzumab
CAS No. 1264737-26-9
Gatipotuzumab( —— )
Catalog No. M37170 CAS No. 1264737-26-9
Gatipotuzumab (PankoMab) is a novel humanized monoclonal antibody conjugated to the tumor-associated epitope of mucin 1 (TA-MUC1) with potential anti-tumor activity for the study of recurrent epithelial ovarian cancer.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 686 | In Stock |
|
| 10MG | 1093 | In Stock |
|
| 25MG | 1606 | In Stock |
|
| 50MG | 2130 | In Stock |
|
| 100MG | 2902 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameGatipotuzumab
-
NoteResearch use only, not for human use.
-
Brief DescriptionGatipotuzumab (PankoMab) is a novel humanized monoclonal antibody conjugated to the tumor-associated epitope of mucin 1 (TA-MUC1) with potential anti-tumor activity for the study of recurrent epithelial ovarian cancer.
-
DescriptionGatipotuzumab (PankoMab) is a humanized monoclonal antibody which recognizes the tumor-specific epitope of mucin-1 (TA-MUC1). Gatipotuzumab reveals a potent tumor-specific antibody-dependent cell cytotoxicity (ADCC).
-
In VitroGatipotuzumab (PankoMab) strongly binds to a short MUC1 peptide of 30 amino acids comprising 1.5 TRs when it is glycosylated with GalNAcα at the T of the PDTRP-sequence, but not if the same peptide is not glycosylated.Gatipotuzumab (PankoMab) (1 h) has a high-affinity towards tumour cells (KD of 0.91, 3.03, 3.84 and 7.14 nM towards NM-D4, ZR75-1, MCF-7 and T-47D, respectively).Gatipotuzumab (PankoMab) (0-5 μg/mL; 4 h) shows specific anti-tumor antibody-dependent cell cytotoxicity activity.
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorMucin
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1264737-26-9
-
Formula Weight
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Macchini M, et al. Results from the primary analysis of a 30 patient extension of the GATTO study, a phase Ib study combining the anti-MUC1 gatipotuzumab (GAT) with the anti-EGFR tomuzotuximab (TO) or panitumumab in patients with refractory solid tumors. European Journal of Cancer, 2020, 138: S5-S6.
molnova catalog
related products
-
Cinepazide
A cerebral vasodilator that acts as a calcium blocker.
-
Fulacimstat
Fulacimstat (BAY 1142524, BAY1142524) is a potent, orally available chymase inhibitor with IC50 of 4 nM and 3 nM for human and hamster chymase enzyme, respectively.
-
Intermedin (rat)
Intermedin (rat) is a polypeptide that can be found by peptide screening. Peptide screening is a research tool that pools active peptides primarily by immunoassay. Peptide screening can be used for protein interaction, functional analysis, epitope screening, especially in the field of agent research and development.
Cart
sales@molnova.com